StreetAlpha.app
Home › Stocks › LBRX

LB Pharmaceuticals Inc (LBRX)

$40.30
▼ −6.26%
LAST CLOSE · NOV 17

LB Pharmaceuticals is a New York drug developer focused on LB-102, a candidate for schizophrenia and mood disorders. It last closed at $40.30 on Nov 17, down 6.26% on the day. The average 12-month price target from 5 analysts is $61.60 (+52.9% from the last close), with a high of $80.00 and a low of $35.00. Analyst consensus is Strong Buy, based on the latest ratings from 5 firms (4 buy, 1 hold, 0 sell).

AI Auto Pilots
Is LBRX in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$141.2M
EPS (diluted)
−$1.12
Free cash flow
−$143.8M
Valuation
Market cap
$1.3B
32.4M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$215.1M
At Sep 30
Shareholder equity
$417.6M
Shares outstanding
32.4M
At Nov 3
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2024: −$63.1M−$63.1MFY2024FY2025: −$25.2M−$25.2MFY2025

From LBRX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Last report
Nov 5
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 5 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
5firms
4 Buy1 Hold0 Sell
Each firm's latest rating on LBRX in the past 90 days
Average 12-month target
$61.60
▲ 52.9% upside

Based on 5 analysts who set a price target on LBRX in the past 90 days. The average target is $61.60, with a high of $80.00 and a low of $35.00, compared with the last close of $40.30.

Low $35.00Avg $61.60High $80.00
Blue marker: last close $40.30
Highest target$80.00
Average target$61.60
Lowest target$35.00
Latest rating changes
Canaccord GenuityInitiated
Oct 9Buy$65
GuggenheimInitiated
Oct 6Buy$80
Roth CapitalDowngrade
Oct 5Hold$35
NeedhamInitiated
Oct 2Buy$68
HC Wainwright & Co.Target raised
Aug 24Buy$45 → $60
DateFirmActionRatingPrice target
Oct 9Canaccord GenuityInitiatedBuy$65
Oct 6GuggenheimInitiatedBuy$80
Oct 5Roth CapitalDowngradeHold$35
Oct 2NeedhamInitiatedBuy$68
Aug 24HC Wainwright & Co.Target raisedBuy$45 → $60
Loading…

Technical Analysis

LBRX · as of the Nov 17 close · updated after every close
Uptrend

The stock sits between its 20 and 50 day averages. It is 16% above its 200 day average, so the longer trend is still up. Momentum is improving (RSI 48). The nearest support is the 50 day average at $39.88, and the nearest resistance the 100 day average at $40.37.

Short trendBullish
Long trendBullish
MomentumImproving
StretchNormal
VolatilityNormal, 6.7%/day
Key levels
$50.1652 week high+24.5%
$43.26Pivot R1+7.3%
$41.58Swing high (Oct 22)+3.2%
$41.05Pivot+1.9%
$40.9920 day average+1.7%
$40.37100 day average+0.2%
$40.30Last close
$39.8850 day average−1.0%
$38.08Pivot S1−5.5%
$38.03Swing low (Nov 5)−5.6%
$33.78200 day average−16.2%
$15.1352 week low−62.5%
Indicators
RSI (14)48.20Middle of its rangeNeutral
MACD0.97Above its signal lineBullish
Stochastic51.2Middle of its rangeNeutral
ADX (14)25.6Trending down
Williams %R-71.5Oversold below −80, overbought above −20Neutral
CCI (20)0.5Oversold below −100, overbought above 100Neutral
Rate of change−0.1%Change over 10 sessionsBearish
ATR (14)$2.69Typical daily range, 6.7% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Below
MA 200Above
What happened before, for LBRX

What happened before

See how LBRX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Whale Options Flow

90D

No whale options trades in LBRX in the last 90 days.

Loading…

See today’s whale options flow across the market →

LBRX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲99 buying vs 40 selling
  • ▲Held by funds +10.2 pts
  • ▲Funds holding +32
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding147115+27.8%
In funds' top 1075+40.0%
Held by funds105.4%95.2%+10.2 pts
New / increased42 / 5741 / 42+19.3%
Reduced / sold out29 / 1113 / 3+150.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See LBRX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether LBRX is in one of them and how their past LBRX trades turned out.

LBRX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered LBRX in an article yet. Here's the latest on the wider market.

About LB Pharmaceuticals

LB Pharmaceuticals is a biopharmaceutical company based in New York that develops treatments for neuropsychiatric disorders. Its main product candidate, LB-102, is in late-stage testing for schizophrenia and bipolar depression, with a planned study in major depressive disorder as a supplemental treatment. LB-102 is a chemical relative of amisulpride, an antipsychotic already used in many countries outside the United States. The company aims to offer its treatments to patients and to the psychiatrists who prescribe for them.

Headquarters
New York, NY